On March 10, 2026, Rodman & Renshaw initiated coverage of Elicio Therapeutics (NasdaqCM:ELTX) with a Buy recommendation, suggesting a potential upside of 22.56%. The average one-year price target for the company is set at $15.81 per share, up from the latest closing price of $12.90. The forecast range is between $13.13 and $18.90.
As of February 25, 2026, Elicio Therapeutics is projected to generate annual revenue of $15 million, with a non-GAAP EPS estimated at -$2.09. Institutional positions in the company decreased by 4 funds or 8.7% to 42 funds in the last quarter, although total shares owned by institutions increased by 0.84% to 1.995 million shares. The put/call ratio stands at 0.18, indicating a bullish sentiment towards the stock.
